Do Your Legs Feel Heavy, Swollen and Sore?
You could be experiencing the first signs of Chronic Venous Insufficiency. Daflon helps reduce and relieve the following signs and symptoms associated with this progressive condition 2,5 :
Looks familiar?
Take our quick self-assessment quiz and use your result to self-help guide your next steps.
Do you suffer from anal pain, bleeding and itching?
You could be experiencing the uncomfortable anal pain, itching and bleeding. Daflon acts quickly to reduce and relieve the following signs and symptoms of acute and recurring anal pain: 1,3
Safety Information:
Daflon 500mg Safety Information
COMPOSITION*: Micronized, purified flavonoid fraction 500 mg: 450 mg diosmin; 50 mg flavonoids expressed as hesperidin.
INDICATIONS*: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of acute hemorrhoidal attacks.
DOSAGE AND ADMINISTRATION*: In venous disease: 2 tablets daily. In acute hemorrhoidal attacks: the dosage can be increased to up to 6 tablets daily.
CONTRAINDICATIONS*: Hypersensitivity to the active substance or to any of the excipients.
WARNINGS*: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.
INTERACTION(S)*: None.
FERTILITY*. PREGNANCY/LACTATION*: Treatment should be avoided.
DRIVE & USE MACHINES*. UNDESIRABLE EFFECTS*: Common: diarrhoea, dyspepsia, nausea, vomiting. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Uncommon: colitis. Frequency not known abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke’s oedema.
OVERDOSE*. PROPERTIES*: Vascular protector and venotonic. Daflon 500 mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.
PRESENTATION*: Pack of 30 film-coated tablets of Daflon 500 mg.
Servier Hong Kong Limited Room 103, 31/F, The Gateway Tower 5, 15 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong. www.servier.hk
*For complete information, please refer to the Summary of Product Characteristics.
Daflon 1000mg Safety Information
COMPOSITION*: Micronized, purified flavonoid fraction 1000 mg: 900 mg diosmin; 100 mg flavonoids expressed as hesperidine.
INDICATIONS*: Treatment of the symptoms of chronic venous disease of the lower limbs, either organic or functional: feeling of heavy legs, pain, night cramps. Treatment of acute hemorrhoidal episodes.
DOSAGE AND ADMINISTRATION*: In venous disease: 1000mg daily. In acute hemorrhoidal attacks: the dosage can be increased up to 3000mg daily.
CONTRAINDICATIONS*: Hypersensitivity to the active substance or to any of the excipients.
WARNINGS*: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.
INTERACTION(S)*: None.
FERTILITY/PREGNANCY/LACTATION*: Treatment should be avoided.
DRIVE & USE MACHINES/UNDESIRABLE EFFECTS*: Common: diarrhoea, dyspepsia, nausea, vomiting. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Uncommon: colitis. Frequency not known abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke’s oedema.
OVERDOSE/PROPERTIES*: Vascular protector and venotonic. Daflon 500 mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.
PRESENTATION*: Pack of 30 film-coated tablets of Daflon 500 mg.
Servier Hong Kong Limited Room 103, 31/F, The Gateway Tower 5, 15 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong. www.servier.hk
*For complete information, please refer to the complete Summary of Product Characteristics for your country.
References:
- Shelygin Y, et al. Curr Med Res Opin. 2016;32(11):1821-1826. DOI: 10.1080/03007995.2016.1211520.
- Nicolaides A, et al. Part I. Int Angiol. 2018;37(3):181-254.
- Godeberge P, et al. J Comp Eff Res 2021;10(10):801-813.
- Godeberge P, et al., J. Gastroenterol and Hepatol. 2020; 35:577-585. DOI:10.1111/jgh.14857.
- Nicolaides A, et al. International Angiology. 2020 Part II; DOI: 10.23736/S0392-9590.20.04388-6.
2024